Characteristics of gastric cancer according to Helicobacter pylori infection status

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 9, 2014, Pages 1671-1677

  Kwak, Hee Won ^a   Choi, Il Ju ^a   Cho, Soo Jeong ^a   Lee, Jong Yeul ^a   Kim, Chan Gyoo ^a   Kook, Myeong Cherl ^a   Ryu, Keun Won ^a   Kim, Young Woo ^a  

^a National Cancer Center   (South Korea)

Author keywords

Atrophy; Gastric cancer; Helicobacter pylori; Intestinal metaplasia

Indexed keywords

UREASE;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; ENDOSCOPIC SURGERY; FEMALE; GASTRECTOMY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RAPID UREASE TEST; SEROLOGY; STOMACH ADENOCARCINOMA; STOMACH ATROPHY; AGE; COMORBIDITY; GASTRITIS; KOREA; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SEX DIFFERENCE; STOMACH NEOPLASMS;

ADULT; AGE FACTORS; AGED; COMORBIDITY; FEMALE; GASTRITIS; HELICOBACTER INFECTIONS; HUMANS; KOREA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX FACTORS; STOMACH NEOPLASMS;

EID: 84905441630     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12605     Document Type: Article

References (48)

1. de Martel C, Ferlay J, Franceschi S etal. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012; 13: 607-615.
2. Uemura N, Okamoto S, Yamamoto S etal. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001; 345: 784-789.
3. Cho SJ, Choi IJ, Kim CG etal. Helicobacter pylori seropositivity is associated with gastric cancer regardless of tumor subtype in Korea. Gut Liver 2010; 4: 466-474.
4. Wong BC, Lam SK, Wong WM etal. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291: 187-194.
5. Yamamoto K, Kato M, Takahashi M etal. Clinicopathological analysis of early-stage gastric cancers detected after successful eradication of Helicobacter pylori. Helicobacter 2011; 16: 210-216.
6. Romero-Gallo J, Harris EJ, Krishna U, Washington MK, Perez-Perez GI, Peek RM. Effect of Helicobacter pylori eradication on gastric carcinogenesis. Lab. Invest. 2008; 88: 328-336.
7. Mera R, Fontham ET, Bravo LE etal. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005; 54: 1536-1540.
8. Choi IJ. Current evidence of effects of Helicobacter pylori eradication on prevention of gastric cancer. Korean J. Intern. Med. 2013; 28: 525-537.
9. Yoon H, Kim N, Lee HS etal. Helicobacter pylori-negative gastric cancer in South Korea: incidence and clinicopathologic characteristics. Helicobacter 2011; 16: 382-388.
10. Kato S, Matsukura N, Tsukada K etal. Helicobacter pylori infection-negative gastric cancer in Japanese hospital patients: incidence and pathological characteristics. Cancer Sci. 2007; 98: 790-794.
11. Matsuo T, Ito M, Takata S, Tanaka S, Yoshihara M, Chayama K. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter 2011; 16: 415-419.
12. Xue LJ, Su QS, Yang JH, Lin Y. Autoimmune responses induced by Helicobacter pylori improve the prognosis of gastric carcinoma. Med. Hypotheses 2008; 70: 273-276.
13. Meimarakis G, Winter H, Assmann I etal. Helicobacter pylori as a prognostic indicator after curative resection of gastric carcinoma: a prospective study. Lancet Oncol. 2006; 7: 211-222.
14. Marrelli D, Pedrazzani C, Berardi A etal. Negative Helicobacter pylori status is associated with poor prognosis in patients with gastric cancer. Cancer 2009; 115: 2071-2080.
15. Park DW, Lee KJ, Jin SH etal. Phenotypic differences of gastric cancer according to the Helicobacter pylori infection in Korean patients. J. Gastric Cancer 2010; 10: 168-174.
16. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am. J. Surg. Pathol. 1996; 20: 1161-1181.
17. Kim CG, Choi IJ, Lee JY etal. Biopsy site for detecting Helicobacter pylori infection in patients with gastric cancer. J. Gastroenterol. Hepatol. 2009; 24: 469-474.
18. Said RM, Cheah PL, Chin SC, Goh KL. Evaluation of a new biopsy urease test: Pronto Dry, for the diagnosis of Helicobacter pylori infection. Eur. J. Gastroenterol. Hepatol. 2004; 16: 195-199.
19. Basso D, Stefani A, Brigato L etal. Serum antibodies anti-H. pylori and anti-CagA: a comparison between four different assays. J. Clin. Lab. Anal. 1999; 13: 194-198.
20. Rugge M, Genta RM. Staging gastritis: an international proposal. Gastroenterology 2005; 129: 1807-1808.
21. Capelle LG, de Vries AC, Haringsma J etal. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest. Endosc. 2010; 71: 1150-1158.
22. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. American Joint Committee on Cancer Staging Manual, 7th edn. New York: Springer, 2010; 117-126.
23. Kakinoki R, Kushima R, Matsubara A etal. Re-evaluation of histogenesis of gastric carcinomas: a comparative histopathological study between Helicobacter pylori-negative and H. pylori-positive cases. Dig. Dis. Sci. 2009; 54: 614-620.
24. Nasrollahzadeh D, Aghcheli K, Sotoudeh M etal. Accuracy and cut-off values of pepsinogens I, II and gastrin 17 for diagnosis of gastric fundic atrophy: influence of gastritis. PLoS One 2011; 6: e26957.
25. Kim N, Jung HC. The role of serum pepsinogen in the detection of gastric cancer. Gut Liver 2010; 4: 307-319.
26. Gill S, Shah A, Le N, Cook EF, Yoshida EM. Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a Canadian cancer center. J. Clin. Oncol. 2003; 21: 2070-2076.
27. Strong VE, Song KY, Park CH etal. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann. Surg. 2010; 251: 640-646.
28. Hansen S, Vollset SE, Derakhshan MH etal. Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. Gut 2007; 56: 918-925.
29. Ye W, Held M, Lagergren J etal. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J. Natl. Cancer Inst. 2004; 96: 388-396.
30. Sipponen P. Update on the pathologic approach to the diagnosis of gastritis, gastric atrophy, and Helicobacter pylori and its sequelae. J. Clin. Gastroenterol. 2001; 32: 196-202.
31. Kang HY, Kim N, Park YS etal. Progression of atrophic gastritis and intestinal metaplasia drives Helicobacter pylori out of the gastric mucosa. Dig. Dis. Sci. 2006; 51: 2310-2315.
32. Asaka M, Kato M, Kudo M etal. Atrophic changes of gastric mucosa are caused by Helicobacter pylori infection rather than aging: studies in asymptomatic Japanese adults. Helicobacter 1996; 1: 52-56.
33. Luzza F, Parrello T, Monteleone G etal. Up-regulation of IL-17 is associated with bioactive IL-8 expression in Helicobacter pylori-infected human gastric mucosa. J. Immunol. 2000; 165: 5332-5337.
34. Serelli-Lee V, Ling KL, Ho C etal. Persistent Helicobacter pylori specific Th17 responses in patients with past H. pylori infection are associated with elevated gastric mucosal IL-1beta. PLoS One 2012; 7: e39199.
35. Maruyama T, Kono K, Mizukami Y etal. Distribution of Th17 cells and FoxP3(+) regulatory T cells in tumor-infiltrating lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer. Cancer Sci. 2010; 101: 1947-1954.
36. Veenendaal RA, Pena AS, Meijer JL etal. Long term serological surveillance after treatment of Helicobacter pylori infection. Gut 1991; 32: 1291-1294.
37. Kosunen TU, Seppala K, Sarna S, Sipponen P. Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori. Lancet 1992; 339: 893-895.
38. Koizumi W, Tanabe S, Imaizumi H etal. Effect of anti-Helicobacter pylori IgG antibody titer following eradication of Helicobacter pylori infection. Hepatogastroenterology 2003; 50: 293-296.
39. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001; 49: 347-353.
40. Qiu HB, Zhang LY, Keshari RP etal. Relationship between H.pylori infection and clinicopathological features and prognosis of gastric cancer. BMC Cancer 2010; 10: 374.
41. Correa P. Helicobacter pylori and gastric carcinogenesis. Am. J. Surg. Pathol. 1995; 19 (Suppl. 1): S37-43.
42. Takenaka R, Okada H, Kato J etal. Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type. Aliment. Pharmacol. Ther. 2007; 25: 805-812.
43. Ogura K, Hirata Y, Yanai A etal. The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. J. Clin. Gastroenterol. 2008; 42: 279-283.
44. Zheng H, Takahashi H, Murai Y etal. Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray. J. Clin. Pathol. 2007; 60: 273-277.
45. Kamangar F, Dawsey SM, Blaser MJ etal. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J. Natl. Cancer Inst. 2006; 98: 1445-1452.
46. Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998; 114: 1169-1179.
47. Nordenstedt H, Graham DY, Kramer JR etal. Helicobacter pylori-negative gastritis: prevalence and risk factors. Am. J. Gastroenterol. 2013; 108: 65-71.
48. Haber MM, Hunt B, Freston JW etal. Changes of gastric histology in patients with erosive oesophagitis receiving long-term lansoprazole maintenance therapy. Aliment. Pharmacol. Ther. 2010; 32: 83-96.